Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention.

NPJ Breast Cancer · 2025 · PMC12149318 · PMID 40490470

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In ER-positive early breast cancer women, our group observed that exemestane displayed a highly significant median 10% absolute reduction in Ki-67 LI, whereas no change there was with celecoxib or placebo 69 .

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.